Navigation Links
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment

ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final results of the PROVE3 study will be presented at this year's annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and ribavirin.

According to John McHutchison, MD, principal investigator for this study, "This was the first large scale study performed in nonresponders to our current standard of care, which evaluated retreating these patients with the addition of an HCV-specific protease inhibitor. Its importance is, therefore, the proof of principle that adding this potent direct anti-viral allowed us to cure approximately 50 percent of this patient population who have failed therapy and for which no other options currently exists."

The study included 453 patients, and the SVR rates in all treatment groups who received the telaprevir-based therapy were significantly higher than those who received peginterferon alfa-2a and ribavirin. All patients who received telaprevir and achieved virologic response maintained it for 48 weeks after the end of the treatment.

The drug in this nonresponder setting is currently undergoing phase 3 large-scale registration trials to confirm and further elucidate the findings of this current phase 2 study. "To sit across the desk from our hepatitis C patients and tell those that have not responded that with this retreatment strategy they have a 50 percent chance of being cured will be a huge message for patients and providers if confirmed in larger phase 3 clinical trials," concluded Dr. McHutchison.

Abstract title:

PROVE3 final results and 1-year durability of SVR with Telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior nonresponse, viral breakthrough or relapse to Peginterferon-alfa-2a/b and Ribavirin therapy


AASLD is the leading medical society focused solely on advancing the science and practice of hepatology and represents more than 3,300 practitioners, researchers, and allied health professionals worldwide. Founded by physicians in 1950, AASLD has upheld the standards of the profession and fostered research that generates treatment options for the millions of patients with liver diseases.

This year's Liver Meeting, held in Boston, Massachusetts, October 30 - November 3, will bring together more than 7,000 researchers from 55 countries. A pressroom will be available from October 31 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Tracy at 703-299-9766.

Press releases, additional information for the media, and all abstracts are available at

    Press Room: October 31 - November 3, 2009
    Hynes Convention Center, Room 209
    Telephone: 617-954-2827

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit

SOURCE American Association for the Study of Liver Diseases (AASLD)

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
3. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
7. Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
10. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
11. EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimers Disease Patient
Post Your Comments:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):